DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
当前地点:
>
> This Story


注册记数器 to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Rad Oncology Homepage

Japanese startup to develop ultra-compact proton therapy system Designed to replace conventional radiotherapy systems

FDA okays Philips' MR-only radiotherapy simulator, MRCAT pelvis Create treatment plans for bladder, rectal, anal and cervical cancer

Varian to acquire Cancer Treatment Services International for $283 million Enables production of multidisciplinary solutions

Varian acquires CyberHeart, enters cardiac radioablation market Emerging technology could benefit treatment of irregular heartbeats

New 12-year study highlights value of PRRT, based on long-term outcomes Understanding peptide receptor radionuclide therapy

RefleXion Medical secures $60 million for approval and launch of BgRT system Can detect and treat multiple tumors in the same session

Korean cancer center aims to deploy heavy ion therapy in 2022 Plans also call for the onboarding of more CR and MR systems

Radiation oncologists appeal to Congress to safeguard radiotherapy treatment Protecting cancer patients' access to value-based care

Using ERISA to end proton therapy denials Insights from Timothy J. Rozelle and Lisa S. Kantor, from Kantor & Kantor, LLP on getting insurers to provide coverage

Philips unveils IntelliSpace Radiation Oncology system at ESTRO Manages complexity and efficiency of radiology departments

Precision-based medicine improves outcomes and drives down costs

From the June 2017 issue of DOTmed HealthCare Business News magazine

Insurers may be more apt to approve precision medicine techniques when considering a cost-benefit analysis. For cancer patients, expenses will drop as they receive targeted medication within days of diagnosis, and are able to skip more toxic treatments that result in hospitalization, intravenous lines, complications of those, steroids and other medication to lessen side effects and nursing. For example, a report by PricewaterhouseCoopers indicates that a genetic test on breast cancer patients could save an estimated $1,900 per patient because it can reduce chemotherapy use between 20 and 35 percent. Likewise, increased diagnostic accuracy for cancer screenings will reduce the costs and morbidity associated with false positive tests.

In hospitals, where insurance reimbursement rates depend upon patient experience and satisfaction, and expenditures are always closely monitored, precision medicine is already improving outcomes. In one study, precision medicine was shown to reduce readmissions by 52 percent, reduce visits to the emergency department by 42 percent and decrease deaths by 85 percent. Hospitals have a responsibility to their patients (and shareholders) to proactively promote new advancements in medicine. They should utilize their considerable clout to support research and development companies during FDA trials to ensure their physicians have access to the latest precision therapies once approved.
Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.




With the passage of the 21st Century Cures Act, precision medicine has received the backing of the U.S. government. The bill, which provides $4.8 billion in funding to initiatives aimed at matching patients to treatments based on their genes, signals a shift toward creating new health care standards. With the ability to fund more genetic sequencing, it is my hope that we can develop new treatment and diagnostic approaches for a wide range of cancers.

About the author:
Paul Crowe is chairman and CEO of Nuview Life Sciences. Crowe is an experienced health care executive who, over the past 40 years, participated in the commercialization of new diagnostic imaging technologies such as diagnostic ultrasound, magnetic resonance imaging and positron emission tomography (PET). These technologies provided physicians with better tools to more effectively diagnose, and subsequently treat, chronic human diseases, improved patient outcomes and lowered health care costs.

Back to HCB News
<< Pages: 1 - 2

Rad Oncology Homepage


You Must Be Logged In To Post A Comment

做广告
提升您的品牌知名度
拍卖+私人销售
获得最好的价格
买设备/配件
找到最低价格
每日新闻
阅读最新信息
目录
浏览所有的DOTmed用户
DOTmed上的伦理
查看我们的伦理计划
金子分开供营商节目
接收PH要求
金子服务经销商节目
接收请求
提供保健服务者
查看所有的HCP(简称医疗保健提供商)的工具
工作/训练
查找/申请工作
Parts Hunter +EasyPay
获取配件报价
最近证明
查看最近通过认证的用户
最近额定
查看最近通过认证的用户
出租中央
租用设备优惠
卖设备/配件
得到最划算
服务技术员论坛
查找帮助和建议
简单的征求建议书
获取设备报价
真正商业展览
查找对设备的服务
对这个站点的通入和用途是受期限和条件我们支配 法律公告 & 保密性通知
物产和业主对 DOTmed.com,公司 Copyright ©2001-2019 DOTmed.com, Inc.
版权所有